FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Только для исследовательских целей. Полный disclaimer →

Библиотека пептидов

Pinealon

EDR peptide / Glu-Asp-Arg

Longevity & Anti-Aging

Pinealon is a short synthetic tripeptide (Glu-Asp-Arg) developed by Professor Vladimir Khavinson as part of the bioregulator peptide class, designed to target and normalize pineal gland function. It belongs to a family of ultrashort peptides theorized to penetrate cell nuclei and interact directly with DNA to regulate gene expression in specific tissue types. Primary research applications include circadian rhythm regulation, neuroprotection, and normalization of melatonin synthesis in aging populations.

Механизм действия

Synthetic tripeptide bioregulator that penetrates cell membranes and interacts with DNA in the promoter region of genes involved in neurodifferentiation. Promotes neuronal survival, reduces oxidative stress in brain tissue, and modulates circadian rhythm via pineal gland function.

Протоколы исследований

Только для исследовательских целей. Не медицинская консультация.

Research protocols (Khavinson method) use 10-20mg orally or sublingually daily for 10-30 day cycles. Sublingual administration may improve bioavailability. Cycles repeated every 3-6 months.

Примечания к исследованиям

Clinical Research Status

Pinealon has been studied primarily in Russian clinical research settings, with publications appearing in Russian biomedical journals and the St. Petersburg Institute of Bioregulation and Gerontology. Clinical studies in elderly patients have reported improvements in sleep quality, cognitive function, and normalization of melatonin cycling following oral or intranasal administration. It is registered and available as a dietary supplement in Russia but has not undergone Western regulatory review or FDA evaluation.

Key Published Findings

Research by Khavinson's group demonstrates that Pinealon can penetrate cell membranes and nuclear envelopes to interact with specific DNA sequences, potentially regulating gene expression related to pineal gland function. In vitro studies show the peptide promotes neuronal survival under oxidative stress conditions and normalizes circadian gene expression patterns. Animal studies indicate restoration of melatonin synthesis capacity in aged rats and improvement of learning and memory in models of accelerated aging.

Safety Profile

As a naturally occurring amino acid sequence found in human tissue, Pinealon is reported to have an excellent safety profile with no documented adverse effects in available clinical literature. The tripeptide structure is rapidly metabolized into constituent amino acids (glutamic acid, aspartic acid, arginine), minimizing accumulation risk. No drug interactions have been formally documented, though caution is theoretically warranted when combining with exogenous melatonin or other sleep-modulating compounds.

Comparison to Related Compounds

Pinealon differs from exogenous melatonin supplementation by theoretically restoring endogenous melatonin production capacity rather than simply replacing the hormone. Compared to the related Khavinson peptide Epithalon (which targets telomerase in the pineal gland), Pinealon focuses on functional normalization rather than cellular longevity mechanisms. Within the bioregulator peptide family, each compound is tissue-specific: Pinealon targets the pineal gland, Cortexin targets the brain cortex, and Retinalamin targets the retina.

Community Observations

Users typically report improved sleep onset latency and sleep quality within 1-2 weeks of sublingual or intranasal administration. Some users prefer Pinealon over exogenous melatonin due to the absence of morning grogginess and more natural-feeling sleep architecture. Sourcing is primarily limited to Russian pharmacies or specialized peptide suppliers, with quality verification being a common concern in the community.

Половая жизнь

~15-30 minutes

Реконституция

N/A (typically oral/sublingual capsule)

Хранение

Лиофилизированный

Room temperature. Protect from moisture.

Реконститутированный

N/A (oral form)

Юридический статус США

Research chemical (not FDA-approved)

Также известен как

EDR peptideGlu-Asp-Arg

Часто задаваемые вопросы

Что такое Pinealon?

Pinealon is a short synthetic tripeptide (Glu-Asp-Arg) developed by Professor Vladimir Khavinson as part of the bioregulator peptide class, designed to target and normalize pineal gland function. It belongs to a family of ultrashort peptides theorized to penetrate cell nuclei and interact directly with DNA to regulate gene expression in specific tissue types. Primary research applications include circadian rhythm regulation, neuroprotection, and normalization of melatonin synthesis in aging populations.

Как действует Pinealon?

Synthetic tripeptide bioregulator that penetrates cell membranes and interacts with DNA in the promoter region of genes involved in neurodifferentiation. Promotes neuronal survival, reduces oxidative stress in brain tissue, and modulates circadian rhythm via pineal gland function.

Каков регуляторный статус Pinealon в США?

Research chemical (not FDA-approved)

Каков период полувыведения Pinealon?

~15-30 minutes

Как ещё называют Pinealon?

EDR peptide, Glu-Asp-Arg

Peptide Contacts предоставляет исследовательские сводки только для информационных целей. Мы не хостим, распространяем или одобряем документацию поставщиков. Все сертификаты анализа, GMP-сертификаты и коммуникации с поставщиками должны быть запрослены и проверены непосредственно покупателем. Ничто на этом платформе не является юридическим, медицинским или профессиональным советом. Пользователи самостоятельно отвечают за проверку квалификаций поставщиков и обеспечение соответствия всем применимым местным, штатным и федеральным законам перед покупкой любых исследовательских химикатов. Использование этой платформы означает принятие полной личной ответственности.

Прочитать полное заявление о неприкосновенности